Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Purity: ≥ 98%
ln Vivo |
To help treat cancer patients, NCTD may be a practical and affordable medication candidate to replace gefitinib[1].In nude mice, NCTD prevents the growth of human gallbladder carcinoma xenografted tumors by causing apoptosis and interrupting the cell cycle in vivo[2].
|
---|---|
Cell Assay |
HCT116 and HT29, two human colon cancer cell lines, were employed as model systems to study the anti-cancer molecular mechanism of NCTD. Using flow cytometry, cell cycle arrest and early/late apoptosis were examined. Western blot analysis was used to measure the amounts of EGFR, phospho-EGFR, c-Met, phospho-c-Met, and other related proteins[1].
|
Animal Protocol |
Subcutaneous GBC-SD cells were used to create the tumor xenograft model of human gallbladder carcinoma in nude mice in vivo. The 5-FU, NCTD, control, and NCTD+5-FU groups of experimental mice were randomly assigned to receive various treatments. The size, growth curve, and inhibitory rate of the tumor were assessed. Light/electron microscopy and flow cytometry were used to evaluate the xenografted tumors' morphological changes, apoptosis, and cell cycle. RT-PCR and the streptavidin-biotin complex (SABC) method were used to determine the expression of the proteins related to apoptosis, Bcl-2, Bax, and survivin, as well as the cell cycle-related proteins cyclin-D1 and p27[2].
|
References |
|
Molecular Formula |
C8H8O4
|
---|---|
Molecular Weight |
168.15
|
CAS # |
29745-04-8
|
SMILES |
O1C2([H])C([H])([H])C([H])([H])C1([H])C1([H])C(=O)OC(C12[H])=O
|
InChi Key |
JAABVEXCGCXWRR-FBXFSONDSA-N
|
InChi Code |
InChI=1S/C8H8O4/c9-7-5-3-1-2-4(11-3)6(5)8(10)12-7/h3-6H,1-2H2/t3-,4+,5-,6+
|
Chemical Name |
(1R,2S,6R,7S)-4,10-dioxatricyclo[5.2.1.02,6]decane-3,5-dione
|
Synonyms |
Endothall anhydride;Norcantharidin
|
Solubility (In Vitro) |
DMSO: ~33 mg/mL (~196.25 mM)
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 5.9471 mL | 29.7354 mL | 59.4707 mL | |
5 mM | 1.1894 mL | 5.9471 mL | 11.8941 mL | |
10 mM | 0.5947 mL | 2.9735 mL | 5.9471 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.